The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study

SIMPLE SUMMARY: We evaluated the efficacy and safety of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKI) (ICI+TKI) in 51 patients with advanced or metastatic renal cell carcinoma (mRCC). In this study, 7.0 months was the median follow-up period. The overall survival rates at...

Descripción completa

Detalles Bibliográficos
Autores principales: Iinuma, Koji, Yamada, Toyohiro, Kameyama, Koji, Taniguchi, Tomoki, Kawada, Kei, Ishida, Takashi, Nagai, Shingo, Enomoto, Torai, Ueda, Shota, Takagi, Kimiaki, Kawase, Makoto, Takeuchi, Shinichi, Kawase, Kota, Kato, Daiki, Takai, Manabu, Nakane, Keita, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913458/
https://www.ncbi.nlm.nih.gov/pubmed/36765903
http://dx.doi.org/10.3390/cancers15030947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913458/
https://www.ncbi.nlm.nih.gov/pubmed/36765903
http://dx.doi.org/10.3390/cancers15030947

Ejemplares similares